Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quisovalimab - Avalo Therapeutics

Next Previous
Drug Profile

Quisovalimab - Avalo Therapeutics

Alternative Names: AEVI-002; Anti-CD258 monoclonal antibody; Anti-LIGHT monoclonal antibody; Anti-TNFSF14-monoclonal-antibody; AVTX-002; CERC 002; MDGN-002; SAR 252067

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko Kirin; La Jolla Institute for Allergy & Immunology
  • Developer Avalo Therapeutics; Kyowa Hakko Kirin; Sanofi; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Antiasthmatics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; COVID-19 pneumonia; Inflammatory bowel diseases; SARS-CoV-2 acute respiratory disease
  • Phase I/II Crohn's disease
  • Clinical Phase Unknown Ulcerative colitis

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Crohn's-disease(Treatment-experienced, In adults) in USA (SC)
  • 26 Jun 2023 Adverse events and efficacy data from a phase II PEAK trial in Asthma released by Avalo Therapeutics
  • 11 May 2023 Avalo Therapeutics completes the phase-II PEAK trial in Asthma (In adults, In the elderly) in USA (SC) (NCT05288504)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top